Courtney Marabella

The combination of Keytruda and chemotherapy improved survival rates in patients with PD-L1—positive metastatic triple-negative breast cancer.

Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.

The novel drug N-803 boosted response to Bacille Calmette-Guérin therapy in patients with non-muscle invasive bladder cancer, a study showed.

TG-1701 monotherapy or added to ublituximab and Ukoniq contributed to early complete responses in patients with B-cell malignancies.

Research found discrepancies between treatment recommended by clinical trial results and treatment that is typically given to patients with mantle cell lymphoma.

Maintenance treatment with Lynparza plus Avastin over Avastin alone provided a certain group of patients with ovarian cancer a substantial survival benefit.

Some patients with early HER2-negative breast cancer at high risk for disease recurrence achieved meaningful benefit with Lynparza after receiving standard of care therapies, such as surgery or chemotherapy.

The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.